Overview

Chidamide Combined With Clad/Gem/Bu With AutoSCT in High Risk Hodgkin & Non-Hodgkin Lymphoma

Status:
Unknown status
Trial end date:
2021-03-30
Target enrollment:
Participant gender:
Summary
This study is to explore the efficacy and safety of ChiCGB conditioning therapy in patients with high-risk Hodgkin and non-Hodgkin lymphoma.
Phase:
Phase 2
Details
Lead Sponsor:
Sichuan University
Treatments:
Busulfan
Cladribine
Gemcitabine